Andra AP fonden trimmed its stake in Edwards Lifesciences Corporation (NYSE:EW) by 51.3% during the second quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 11,500 shares of the medical research company’s stock after selling 12,100 shares during the quarter. Andra AP fonden’s holdings in Edwards Lifesciences Corporation were worth $1,360,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently modified their holdings of the stock. Sabal Trust CO grew its holdings in shares of Edwards Lifesciences Corporation by 0.5% in the 2nd quarter. Sabal Trust CO now owns 2,934 shares of the medical research company’s stock worth $347,000 after acquiring an additional 14 shares during the last quarter. Alps Advisors Inc. grew its holdings in shares of Edwards Lifesciences Corporation by 0.3% in the 2nd quarter. Alps Advisors Inc. now owns 5,102 shares of the medical research company’s stock worth $603,000 after acquiring an additional 14 shares during the last quarter. Alexandria Capital LLC grew its holdings in shares of Edwards Lifesciences Corporation by 1.7% in the 2nd quarter. Alexandria Capital LLC now owns 1,146 shares of the medical research company’s stock worth $136,000 after acquiring an additional 19 shares during the last quarter. M Holdings Securities Inc. grew its holdings in shares of Edwards Lifesciences Corporation by 1.5% in the 1st quarter. M Holdings Securities Inc. now owns 4,132 shares of the medical research company’s stock worth $389,000 after acquiring an additional 62 shares during the last quarter. Finally, First Bank & Trust grew its holdings in shares of Edwards Lifesciences Corporation by 1.7% in the 2nd quarter. First Bank & Trust now owns 4,439 shares of the medical research company’s stock worth $525,000 after acquiring an additional 76 shares during the last quarter. Institutional investors and hedge funds own 82.36% of the company’s stock.

TRADEMARK VIOLATION WARNING: This report was originally published by TheOlympiaReport and is the sole property of of TheOlympiaReport. If you are reading this report on another domain, it was copied illegally and reposted in violation of international trademark & copyright laws. The correct version of this report can be read at https://theolympiareport.com/2017/09/06/andra-ap-fonden-sells-12100-shares-of-edwards-lifesciences-corporation-ew.html.

Edwards Lifesciences Corporation (NYSE EW) opened at 111.87 on Wednesday. The firm has a 50-day moving average price of $114.95 and a 200-day moving average price of $108.09. The stock has a market cap of $23.62 billion, a P/E ratio of 33.93 and a beta of 0.64. Edwards Lifesciences Corporation has a 52 week low of $81.12 and a 52 week high of $121.75.

Edwards Lifesciences Corporation (NYSE:EW) last released its earnings results on Wednesday, July 26th. The medical research company reported $1.08 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.88 by $0.20. The firm had revenue of $842 million during the quarter, compared to analysts’ expectations of $839.16 million. Edwards Lifesciences Corporation had a return on equity of 27.17% and a net margin of 22.16%. The company’s revenue was up 10.9% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.76 EPS. On average, equities research analysts predict that Edwards Lifesciences Corporation will post $3.78 EPS for the current year.

In other Edwards Lifesciences Corporation news, VP Larry L. Wood sold 18,960 shares of the stock in a transaction dated Wednesday, August 30th. The stock was sold at an average price of $111.81, for a total transaction of $2,119,917.60. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, VP Donald E. Bobo, Jr. sold 5,600 shares of the stock in a transaction dated Thursday, June 29th. The stock was sold at an average price of $117.15, for a total value of $656,040.00. The disclosure for this sale can be found here. In the last quarter, insiders have sold 130,641 shares of company stock valued at $15,013,114. Corporate insiders own 2.13% of the company’s stock.

A number of brokerages recently issued reports on EW. BidaskClub upgraded Edwards Lifesciences Corporation from a “buy” rating to a “strong-buy” rating in a report on Thursday, June 22nd. Canaccord Genuity restated a “buy” rating and issued a $150.00 target price on shares of Edwards Lifesciences Corporation in a report on Wednesday, June 28th. Zacks Investment Research cut Edwards Lifesciences Corporation from a “buy” rating to a “hold” rating in a report on Thursday, June 8th. Jefferies Group LLC restated a “buy” rating and issued a $115.00 target price on shares of Edwards Lifesciences Corporation in a report on Friday, June 30th. Finally, SunTrust Banks, Inc. lifted their target price on Edwards Lifesciences Corporation to $14.00 and gave the stock a “buy” rating in a report on Monday, July 17th. Six research analysts have rated the stock with a hold rating, seventeen have given a buy rating and one has issued a strong buy rating to the company. The company has a consensus rating of “Buy” and an average target price of $120.75.

Edwards Lifesciences Corporation Profile

Edwards Lifesciences Corporation is a manufacturer of heart valve systems and repair products used to replace or repair a patient’s diseased or defective heart valve. The Company is engaged in patient-focused innovations for structural heart disease and critical care monitoring. Its segments include United States, Europe, Japan and Rest of World.

Institutional Ownership by Quarter for Edwards Lifesciences Corporation (NYSE:EW)

Receive News & Ratings for Edwards Lifesciences Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences Corporation and related companies with Analyst Ratings Network's FREE daily email newsletter.